This is less a “lawsuit overhang” story than a credibility reset on the commercialization model. For a single-product medtech, once payer friction and sales-force churn show up simultaneously, the market usually re-rates the equity from growth optionality to near-term cash-burn risk; that can compress the multiple for several quarters even if no enforcement action ultimately lands. The second-order issue is customer trust: hospitals and physicians become slower to adopt when reimbursement is unstable, which can create a self-reinforcing slowdown that is much harder to reverse than a one-time legal headline.

The immediate tradeable move has probably already been partially captured by the gap-down, so chasing weakness here is lower quality than waiting for either a dead-cat bounce or the next disclosure. The real catalyst path is the next 30-90 days: any additional SEC/DOJ color, a further guide-down, or evidence that approval rates remain impaired would likely trigger another leg lower. Over 6-18 months, the key question is whether Barostim can still justify a premium commercial multiple; if reimbursement remains inconsistent, this becomes a dilution-risk name rather than a growth story.

Contrarian view: plaintiffs’-lawyer announcements often overstate certainty, and the market may be over-anchoring on litigation rather than operational decay. But here the operational evidence is the cleaner signal than the investigation itself, so the burden of proof shifts to management to show sequential improvement in approvals, territory productivity, and retention. If that doesn’t happen by the next earnings cycle, any rebound should be sold into rather than treated as a durable bottom. FCD.UN.TO appears uninvolved; no obvious second-order read-through there.